MYSM1 co-activates androgen receptor (AR) action to promote prostate cancer (Zhu et al, 2007), while MYSM1 inhibits castration-resistant prostate cancer (CRPC) process through PI3K/Akt signaling regulation (Sun et al, 2019). This evidence concerns the gene AR and prostate cancer.